Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation and Depletion (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Depreciation and Depletion for 6 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion rose 8.33% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.1 million, a 4.08% increase, with the full-year FY2024 number at $4.8 million, up 9.09% from a year prior.
  • Depreciation and Depletion was $1.3 million for Q3 2025 at 4D Molecular Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.3 million in Q4 2023 to a low of $300000.0 in Q4 2021.
  • A 5-year average of $900000.0 and a median of $1.1 million in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: surged 233.33% in 2022, then fell 7.69% in 2024.
  • 4D Molecular Therapeutics' Depreciation and Depletion stood at $300000.0 in 2021, then soared by 233.33% to $1.0 million in 2022, then increased by 30.0% to $1.3 million in 2023, then fell by 7.69% to $1.2 million in 2024, then rose by 8.33% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Depreciation and Depletion are $1.3 million (Q3 2025), $1.3 million (Q2 2025), and $1.3 million (Q1 2025).